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Afoxolaner  is  an isoxazoline  compound  characterized  by a good  safety  proﬁle  and  extended
effectiveness  against  ﬂeas  and ticks  on  dogs  following  a single  oral  administration.  In  vitro
membrane  feeding  assay  data  and  in  vivo  pharmacokinetic  studies  in  dogs  established
an  afoxolaner  blood  concentration  of  0.1–0.2  g/ml  to be effective  against  both  ﬂeas
(Ctenocephalides  felis)  and  ticks  (Dermacentor  variabilis).  Pharmacokinetic  proﬁles  in dogs
following  a 2.5  mg/kg  oral  dosage  demonstrated  uniform  and  predictable  afoxolaner  plasma
concentrations  above  threshold  levels  required  for efﬁcacy  for  more  than  one  month.
Dose ranging  and  a 5-month  multi-dose  experimental  study  in  dogs,  established  that  the
2.5 mg/kg  oral  dosage  was  highly  effective  against  ﬂeas  and ticks,  and produced  predictable
and  reproducible  pharmacokinetics  following  repeated  dosing.  Mode  of action  studies
showed  that afoxolaner  blocked  native  and  expressed  insect  GABA-gated  chloride  channels
with nanomolar  potency.  Afoxolaner  has  comparable  potency  between  wild  type  channels
and channels  possessing  the  A302S  (resistance-to-dieldrin)  mutation.  Lack  of  cyclodiene
cross-resistance  for afoxolaner  was conﬁrmed  in comparative  Drosophila  toxicity  studies,
and it  is  concluded  that afoxolaner  blocked  GABA-gated  chloride  channels  via  a site  distinct
from  the  cyclodienes.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB
. Introduction
To date, no therapeutic compound administered per os
as had the attributes required to effectively kill both ﬂeas
nd ticks on dogs safely for a month or more (Beugnet and
ranc, 2012). Cythioate, an organophosphate, was the ﬁrst
ral agent to kill ﬂeas but the short duration of its efﬁ-
acy (∼1 day; Gordon, 1995), variable efﬁcacy against ﬂeas
Arther et al., 1989), and poor safety proﬁle limited its use.
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304-4017/© 2014 The Authors. Published by Elsevier B.V. This is an open acce
icenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Nitenpyram, a closely related analog of the neonicotinoid,
imidacloprid, has high levels of effectiveness against ﬂeas
only, and its half-life is such that its activity lasts but a sin-
gle day (Cadiergues et al., 1999). Spinosad was the ﬁrst oral
agent to provide month long activity with good effective-
ness but primarily against ﬂeas (Snyder et al., 2007).
Herein, we reveal the structure of afoxolaner, a novel
member of an isoxazoline class of compounds, and describe
the initial preclinical program in dogs against ﬂeas and
ticks using oral administration. Isoxazoline insecticide rep-
resents a new class of potent ectoparasiticides, including
afoxolaner, but also ﬂuralaner, amongst others (Ozoe et al.,
2010; Garcia-Reynaga et al., 2013; Gassel et al., 2014).
ss article under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1. Molecular structure of 
The proof of concept studies presented here were not
conducted with a ﬁnal formulation to be registered as
a veterinary medicine. Initial in vitro studies revealed
remarkable activity of afoxolaner against ﬂeas, and sub-
sequent in vivo testing in dogs demonstrated outstanding
effectiveness against ﬂeas and ticks for an entire month fol-
lowing a single, low dose oral administration. Multi-month
dosing tests further deﬁned the effective oral dosage and
safety of afoxolaner in dogs. Lastly, we outline the insecti-
cidal/acaricidal mode of action of this compound and the
class.
The history of insecticidal isoxazolines can be traced
back to the discovery of the phthalic and the anthranilic
diamides, and Lahm et al. (2013) have recently described
the high levels of activity of a class of 4-azolylphenyl isox-
azoline compounds for agricultural use. The isoxazoline
compounds having both insecticidal and acaricidal activ-
ities have been proven to act on speciﬁc GABA/glutamate
receptor inhibiting the chloride ion channels of arthropods
(Ozoe et al., 2010; Garcia-Reynaga et al., 2013; Gassel et al.,
2014).
The authors discovered a group of naphthalene isoxa-
zoline compounds displaying remarkable activity against
the cat ﬂea (Ctenocephalides felis) and afoxolaner was
selected as a representative compound for further testing
and evaluation. The molecular structures of afoxolaner and
of isoxazoline CPD1, a representative of the azolylphenyl
isoxazoline class, are provided in Fig. 1.
2. Materials and methods
The efﬁcacy of afoxolaner was assessed during different
studies. A ﬁrst in vitro study identiﬁed the potential activity
of afoxolaner. It was followed by studies on dogs. A ﬁrst
simple assessment, then a one-month study, and ﬁnally a
5-months study. In parallel to the dog experiments, mode
of action studies were conducted in insect models.
2.1. In vitro study
2.1.1. Study 1
Fleas are obligate haematophagous insects and there-
fore activity of insecticidal compounds that may  be useful
for their control can be evaluated by exposing them to any
pharmaceutical compound added to the blood on which
they feed (Zakson et al., 2001). This approach was  used to
determine the blood concentration of afoxolaner necessary
to kill ﬂeas.
The titration studies were performed in an in vitro
membrane ﬂea feeding system as generally describedCPD I
er and the isoxazoline, CPD I.
by Zakson et al. (2001). Compounds were formulated in
100% dimethyl sulphoxide (DMSO) to a concentration of
32.0 g/ml and then through serial dilution in DMSO to 16,
8, 4, 2 and 1 g/ml. Following the initial formulation and
serial dilution, each drug sample was  further diluted by
addition of citrated bovine blood (99.2% blood, 0.8% sodium
citrate) to create a ﬁnal dose titration of 0.32, 0.16, 0.08,
0.04, 0.02 and 0.01 g/ml. A vehicle treatment consisting
of 1% DMSO and 99% citrated bovine blood was used for the
control treatment. Each dilution of each drug was done in
triplicate. One hundred C. felis ﬂeas fed through the mem-
brane on the blood containing the compound and counts
of live and dead ﬂeas were made after 24, 48 and 72 h.
2.2. In vivo studies on dogs
2.2.1. Studies 2, 3 and 4
Based on the in vitro activity against ﬂeas (study 1), three
studies were serially conducted to establish and deﬁne the
in vivo activity of this compound against ﬂeas and ticks on
dogs. Initial studies involved single treatments, while sub-
sequent studies evaluated the efﬁcacy of different dosages
and multiple treatments. These studies generally employed
similar methodologies.
In these studies, afoxolaner was  delivered in an oral
solution. This was an experimental formulation, which
provided good solubility of the compound and allowed
for administration of accurate doses. Afoxolaner used in
the studies was  synthesized at DuPont Crop Protection.
Each sample of afoxolaner used in the animal studies was
weighed and then formulated in an experimental vehicle
consisting of DMSO (2% of ﬁnal volume) and propylene
glycol/glycerol formal (3:2) (98% of ﬁnal volume). The
experimental vehicle was  also used as the negative control
in each experiment. A vortexer and sonicating bath were
used, as needed, to achieve true solutions as determined by
visual and, if necessary, microscopic inspection to conﬁrm
that no particles or crystals were present. Different dosages
were used for the various studies. All dosages were admin-
istered orally using a calibrated syringe. Day 0 is deﬁned in
each study as the day of dog treatment.
All ﬂea challenges were performed by placing 100 live,
unfed adult cat ﬂeas, C. felis, onto the dorsal midline of
dogs at various times throughout the studies. Fleas were
removed and counted by combing following 24 h of drug
exposure. Comb counts were performed following the
method described by Zakson et al. (1995).
All tick challenges were performed by placing 50
live, unfed adult American dog ticks, Dermacentor vari-
abilis, onto the dorsal midline of dogs at various times
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Table  1
Effect of afoxolaner in blood to exposed ﬂeas (Ctenocephalides felis) in an artiﬁcial membrane feeding device.
Treatment Evaluation time (h) Mean % ﬂea effectivenessa,b
0.32 g/ml 0.16 g/ml 0.08 g/ml 0.04 g/ml 0.02 g/ml 0.01 g/ml
Afoxolaner 24 100 100 62 33 6 0
48  100 100 97 92 49 14
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a Vehicle control mortality was 1, 2.3 and 2.3% at 24, 48 and 72 h respe
b Each time and concentration was done in triplicate.
hroughout the studies. Ticks were removed, categorized
s dead or alive, and counted by hand and comb following
8 h of drug exposure.
The initial day of the ﬂea or tick challenge is recorded
n the speciﬁc table for each study (Tables 2–6) whereas
he removal of ﬂeas and ticks took place 24 and 48 h later,
espectively. All ﬂea and tick evaluations were blinded.
ffectiveness was calculated at given time points, by
he classic formula (1 − [geo mean ﬂea/tick count treated
ogs − geo mean ﬂea/tick count control dogs]/[geo mean
ea/tick count on control dogs]) × 100.
At a minimum, clinical observations for adverse reac-
ions were performed post-treatment at 30 min, 2 and 4 h,
nd then daily for the duration of each study. Additional
etails were noted in Study 4 (see below).
Afoxolaner plasma levels were determined in each ani-
al  study. At various times during the studies, blood
amples were collected from the dogs and placed in hep-
rinized tubes. The blood samples were centrifuged and the
lasma was separated and immediately frozen.
Plasma was thawed and afoxolaner was extracted from
 50-L aliquot diluted with 450 L of HPLC grade water
n a 2-ml plastic centrifuge tube. The sample was  further
iluted with 500 L of HPLC grade acetonitrile. Samples
ere centrifuged for 5 min  at 14,000 rpm in a microcen-
rifuge tube after vigorous mixing at each step. A 10-L
liquot was then analyzed for afoxolaner by LC/MS/MS. The
C/MS/MS system consisted of a Waters Quattro MicroTM
ass Spectrometer interfaced to a Waters Alliance HT 2795
PLC and equipped with a 2.1 mm × 50 mm,  5 m Zorbax
B C18 column. Afoxolaner was eluted from the column
sing a gradient of water/acetonitrile, each containing 0.1%
ormic acid.
Food and water were provided for all dogs following
SDA guidelines and access to veterinary care was available
hroughout the studies. All testing was performed under
he guidelines set forth by the Institutional Animal Care
nd Use Committee of DuPont (USDA, 2008).
.2.2. Study 2: probe efﬁcacy study in dogs
Afoxolaner was prepared for a dosage of 2.5 mg/kg to
e administered once, orally, at the rate of 0.2 ml/kg. The
ehicle was administered in the same manner. Two  beagle
ogs were used for the study with one randomly assigned
o treatment and the other assigned to vehicle. Flea and
ick challenges were made at periodic intervals over the
ourse of 46 days and counts were performed approxi-
ately 24 h (ﬂeas) or 48 h (ticks) after challenge. Blood
amples were taken at least weekly for the duration of the
tudy.100 100 96 46
2.2.3. Study 3: preliminary dosage titration in dogs and
assessment of post prandial effect
Afoxolaner was  prepared for administration at dosages
of 1.5, 2.5 or 3.5 mg/kg to be delivered once, orally at the
rate of 0.2 ml/kg dog weight. The vehicle was administered
in the same manner. Fifteen beagle dogs were allocated
on restricted randomization based on weight and sex to
form 5 equal groups of 3 dogs each. Those groups were allo-
cated randomly to treatment. The treatment groups were:
0 mg/kg fed, 1.5 mg/kg fed, 2.5 mg/kg fed, 2.5 mg/kg fasted
and 3.5 mg/kg fed. In the fed group, food was given prior
to dosing whereas in the fasted group food was removed
the night prior to dosing and not returned until 2 h post-
dosing. Flea and tick challenges were conducted at periodic
intervals over the course of one month. Blood samples were
taken at least weekly for the duration of the study.
2.2.4. Study 4: assessment of 5 month repeat dosing on
efﬁcacy and safety in dogs
Afoxolaner was prepared for a dosage of 2.5 mg/kg to
be administered ﬁve times orally at 30 days intervals at the
rate of 0.2 ml/kg dog weight. The vehicle was administered
in the same manner. Six beagles were allocated randomly
to the 2.5 mg/kg treatment and six beagles were allocated
to treatment with vehicle only. Flea and tick challenges
were made every week over the course of ﬁve months, with
counts conducted at appropriate intervals after each chal-
lenge. Blood samples were taken at least weekly for the
duration of the study. Dog weights were measured on Day
1, and then on Days 7, 14, and 29 of each monthly dosing
cycle. Final weights were collected on Day 31 after the ﬁfth
dose.
At each dosing, dogs were observed at 30 min, 2 and 4 h
post dosing, and daily for the duration of the study (150
days). Each dog had a physical examination by a veterinar-
ian at Day 1, and then on Days 1, 14 and 29 of each monthly
dosing cycle.
2.2.5. Mode of action studies: elucidation of
insecticidal/acaricidal mode of action by evaluation of
toxicity and symptomology in insect models
Initial mode of action studies were conducted using the
related isoxazoline, CPD I, with more detailed studies con-
ducted using afoxolaner (Fig. 1).
2.2.6. Study 5 – toxicity and symptomology in model
insects
Adult male American cockroaches (Periplaneta amer-
icana), were injected with 0.1–10 g CPD I through the
ventral intersegmental membrane of the abdomen with
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Table 2
Flea (Ctenocephalides felis) counts and efﬁcacy of afoxolaner following administration to a dog in an oral solution at 2.5 mg/kg.
Treatment Dosage (mg/kg) Flea counts
Day 1 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42
Vehicle 0 59 75 72 83 73 64 71
Afoxolaner 2.5 0 0 0 0 0 0 0
%  Effectiveness 100 100 100 100 100 100 100
Table 3
Tick (Dermacentor variabilis) counts and efﬁcacy of afoxolaner following administration to a dog in an oral solution at 2.5 mg/kg.
Treatment Dosage (mg/kg) Tick counts
Day 2 Day 9 Day 16 Day 23 Day 30 Day 37 Day 44
Vehicle 0 28 28 32 19 23 27 43
Afoxolaner 2.5 0 0 0 0 0 1 5
%  Effectiveness 100 100 100 100 100 96 88
Table 4
Geometric means and efﬁcacies of afoxolaner against multiple ﬂea (Ctenocephalides felis) challenges following single administration to dogs in an oral
solution.
Treatment Dosage (mg/kg) Fed/fasted n Geometric meana (% efﬁcacyb)
Day 0 Day 7 Day 14 Day 21 Day 28 Day 32
Vehicle 0 Fed 3 81.0 73.1 63.5 67.6 67.5 68.8
Afoxolaner
1.5  Fed 3 0.4 (99.5%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%)
2.5  Fed 3 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.3 (99.6%)
2.5 Fasted 3 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%)
3.5  Fed 3 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.8 (98.8%)
m of the
f each ta Geometric mean is computed by subtracting 1 from the anti-logarith
b Percent efﬁcacy = 100(1 − T/C), where C is GM of vehicle and T is GM o
appropriate concentrations of CPD1 dissolved in 2 L
DMSO. Observations of insect toxicity and mortality were
conducted over a 72 h period and a KD50 (50% knockdown
concentration) was calculated.
2.2.7. Study 6 – cockroach electrophysiology studies
To aid in elucidating the target site of isoxazoline insec-
ticides, activity of CPD I was investigated on an in vitro
preparation. Cockroaches possess an escape reﬂex circuit
(cercal reﬂex) in which mechanical stimulation of hairs of
the cerci produce bursts of action potential spikes which
travel through the ventral nerve cord in an anterior direc-
tion producing excitation of motor nerves (Fig. 4a). Nerve
conduction for this reﬂex circuit involves the excitatory and
inhibitory neurotransmitter receptors, acetylcholine and
GABA, respectively, as well as voltage-gated sodium and
potassium channels.
Table 5
Geometric means and efﬁcacies of afoxolaner against multiple tick (Dermacentor
solution.
Treatment Dosage (mg/kg) Fed/fasted N Geometric mea
Day 2 
Vehicle 0 Fed 3 26.8 
Afoxolaner
1.5  Fed 3 0.4 (98.4%) 
2.5  Fed 3 0.3 (99.0%) 
2.5  Fasted 3 0.3 (99.0%) 
3.5  Fed 3 0.0 (100%) 
a Geometric mean is computed by subtracting 1 from the anti-logarithm of the
b Percent efﬁcacy = 100(1 − T/C), where C is GM of vehicle and T is GM of each t mean of ln(count + 1).
reated group.
Extracellular recordings were conducted on nerve 5
(N5) of the metathoracic ganglion of American cock-
roaches.
2.2.8. Study 7 – oocyte injection and voltage clamp
studies
The fruit ﬂy (Drosophila melanogaster) rdl (resistance-to-
dieldrin) gene encodes for a GABA-gated chloride channel
subunit which can form a functional homomeric chan-
nel that exhibits pharmacology similar to native receptors
(Gassel et al., 2014). To further investigate activity of
afoxolaner, voltage clamp studies were conducted on Xeno-
pus laevis oocytes expressing Drosophila Rdl receptors.
Plasmids pNB40 and pALTER-Ex1 encoding for wild type
(wtRdl) and dieldrin-resistant Rdl (A302SRdl), respectively,
were kindly provided by Prof. David Sattelle (University
of Manchester). Constructs were transformed using One
 variabilis) challenges following single administration to dogs in an oral
na (% efﬁcacyb)
Day 9 Day 16 Day 23 Day 30
23.4 22.9 23.3 23.5
0.4 (98.1%) 0.3 (98.9%) 0.0 (100%) 0.3 (98.9%)
0.3 (98.9%) 0.0 (100%) 0.0 (100%) 0.0 (100%)
0.3 (98.9%) 0.0 (100%) 0.3 (98.9%) 0.0 (100%)
0.0 (100%) 0.0 (100%) 0.3 (98.9%) 0.8 (96.5%)
 mean of ln(count + 1).
reated group.
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Table  6
Geometric means and efﬁcacies of 5 repeated monthly dosages of afoxolaner, 2.5 mg/kg, administered to dogs in an oral solution against ﬂeas (Cteno-
cephalides felis).
Treatment Dosage (mg/kg) n Geometric meana (% efﬁcacyb) for Dose 1
Day 0 Day 7 Day 14 Day 21 Day 26
Vehicle 0 6 61.9 58.4 63.4 58.3 60.9
Afoxolaner 2.5 6 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.3 (99.6%)
Treatment Dosage (mg/kg) n Geometric mean (% efﬁcacy) for Dose 2
Day 0 Day 7 Day 14 Day 21 Day 26
Vehicle 0 6 62.8 66.3 65.0 58.5 73.9
Afoxolaner 2.5 6 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%)
Treatment Dosage (mg/kg) n Geometric mean (% efﬁcacy) for Dose 3
Day 0 Day 7 Day 14 Day 21 Day 26
Vehicle 0 6 64.2 63.0 53.5 62.9 71.2
Afoxolaner 2.5 6 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.1 (99.8%)
Treatment Dosage (mg/kg) n Geometric mean (% efﬁcacy) for Dose 4
Day 0 Day 7 Day 14 Day 21 Day 26
Vehicle 0 6 72.9 51.2 70.1 79.0 77.1
Afoxolaner 2.5 6 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.4 (99.5%)
Treatment Dosage (mg/kg) n Geometric mean (% efﬁcacy) for Dose 5
Day 0 Day 7 Day 14 Day 21 Day 26 Day 30
Vehicle 0 6 73.8 73.6 73.4 72.5 69.0 69.9
Afoxolaner 2.5 6 0.0 (100%) 0.1 (99.8%) 0.0 (100%) 0.0 (100%) 0.2 (99.7%) 0.0 (100%)
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hot® Top 10 competent Escherichia coli (Invitrogen) and
DNA puriﬁed using Plasmid Maxi Kit (Qiagen). wtRdl cDNA
as linearized with the restriction endonuclease, NotI and
RNA synthesized with SP6 RNA polymerase. A302SRdl cRNA
as synthesized with T7 RNA polymerase. The cDNA was
ot linearized as there is a T7 RNA polymerase termination
equence 3′ to the Rdl insert.
X. laevis oocytes were isolated from ovaries (purchased
rom Nasco) and defoliculated using 2 mg/ml  collagenase
Type 1A, Sigma) in standard oocyte saline (SOS) having
he following composition (mM):  NaCl 100.0, KCl 2.0, CaCl2
.8, MgCl2 1.0, HEPES 5.0, pH 7.6. Oocytes at growth stage
 or VI were selected for injection with 20 ng of cRNA
ncoding for either wtRdl or A302SRdl using a micro-injector
Nanoject II; Drummond Scientiﬁc). Following injection,
he oocytes were incubated at 18 ◦C in sterile SOS sup-
lemented with 50 g/ml gentamycin sulfate, 100 units/ml
enicillin, 100 g/ml streptomycin and 2.5 mM  sodium
yruvate.
For electrophysiology studies, oocytes were secured in
 Perspex chamber (RC-3Z Warner Instruments). Oocytes
ere impaled with KCl-ﬁlled (3 M)  microelectrodes hav-
ng resistance values of 0.5–1.5 M (current passing) and
–5 M (recording). Membrane currents were recorded
nder two-electrode voltage-clamp mode with a hold-
ng potential of −60 mV  using an Axoclamp 2B ampliﬁer
Molecular Devices) with signal acquisition and processing
sing pClamp software (Molecular Devices). Solutions
ere bath perfused at a rate of 3–5 ml/min with GABA being mean of ln(count + 1).
d group.
applied at 2 min intervals. DMSO concentrations for test
solutions did not exceed 0.1%.
2.2.9. Study 8 – cross-resistance studies
To evaluate whether there was  potential for cross-
resistance with cyclodienes, afoxolaner was evaluated in
a contact toxicity study using wild type (Canton-S) and
cyclodiene-resistant (Rdl) strains of Drosophila with dield-
rin included for comparison. Both strains of Drosophila were
obtained from Bloomington Drosophila Stock Center (Indi-
ana University). Afoxolaner and dieldrin were dissolved
in acetone and a 150 l volume of test solution was  dis-
pensed into 12 ml  glass vials. The vials were rotated on a
carousel to evenly distribute afoxolaner and dieldrin while
the acetone evaporated. Ten adult female Drosophila (less
than 2 weeks post-emergence), were transferred into each
test vial which was  then sealed with a saturated cotton
wick (10% sucrose). Mortality (moribund individuals were
counted as dead) was measured at 72 h. A minimum of 3
replicates was obtained for each concentration along with
an acetone control.
3. Results
3.1. In vitro study 1A dosage and time titration effect was  clearly identiﬁed
for ﬂeas ingesting afoxolaner with mean efﬁcacies of >95%
recorded for ﬂeas fed blood containing the compound at
y Parasitology 201 (2014) 179–189
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concentrations of 0.16, 0.08 and 0.02 g/ml at the 24, 48
and 72 h observation points, respectively (Table 1). There
was only 1%, 2.3% and 2.3% mean mortality in the vehicle-
treated control at the 24, 48 and 72 h observation points,
respectively. Therefore, afoxolaner was judged to be highly
active against ﬂeas following ingestion in blood.
3.2. Study 2: probe efﬁcacy study in dogs
The percent reduction in ﬂea counts in the afoxolaner-
treated dog following 6 weekly ﬂea challenges was 100%
(Table 2). Percent reduction in tick counts in the afoxolaner-
treated dog, following the ﬁrst 5 tick challenges on Days 2,
7, 14, 21 and 28, was 100%. The effectiveness of the drug
declined slightly to 96% on Day 37 and then to 88% on Day
44 (Table 3). No adverse events were noted during this
experiment.
3.3. Study 3: preliminary dosage titration in dogs and
assessment of post prandial effect
Mean percent reduction in ﬂea counts for the four
afoxolaner treatment groups challenged throughout the
study (ﬂea infestations on Days 1, 7, 14, 21, and 28)
ranged from 99% to 100% (Table 4). Mean percent reduc-
tion in ﬂea counts on day 32 was 100, 99, 100, and 99%
for the 1.5 mg/kg fed, 2.5 mg/kg fed, 2.5 mg/kg fasted and
3.5 mg/kg fed groups, respectively (Table 4). Mean percent
reduction in tick counts for the four afoxolaner treatment
Table 7
Geometric means and efﬁcacies of 5 repeated monthly dosages of afoxolaner, 2.5 m
variabilis).
Treatment Dosage (mg/kg) n Geometric meana (% efﬁ
Day 2 Day 9
Vehicle 0 6 15.7 37.9 
Afoxolaner 2.5 6 2.6 (83.5%) 0.1 
Treatment Dosage (mg/kg) n Geometric mean (% efﬁcac
Day 2 Day 9 
Vehicle 0 6 29.7 22.6 
Afoxolaner 2.5 6 0.0 (100%) 0.4 (9
Treatment Dosage (mg/kg) n Geometric mean (% efﬁcac
Day 2 Day 9 
Vehicle 0 6 16.3 20.9 
Afoxolaner 2.5 6 0.3 (98.4%) 0.5 (9
Treatment Dosage (mg/kg) n Geometric mean (% efﬁca
Day 2 Day 9 
Vehicle 0 6 19.1 21.9 
Afoxolaner 2.5 6 0.1 (99.4%) 0.1 (9
Treatment Dosage (mg/kg) n Geometric mean (% efﬁca
Day 2 Day 9
Vehicle 0 6 24.3 26.7 
Afoxolaner 2.5 6 0.0 (100%) 0.1 (
a Geometric mean is computed by subtracting 1 from the anti-logarithm of the
b Percent efﬁcacy = 100(1 − T/C), where C is GM of vehicle and T is GM of treateFig. 2. Mean pharmacokinetic proﬁles of afoxolaner following adminis-
tration to fed or fasted dogs in an oral solution (5 dogs/group).
groups challenged at intervals throughout the study (Days
2, 9, 16, 23 and 30) ranged from 97% to 100% (Table 5). Mean
percent reduction in tick counts at Day 30 was  99, 100,
100 and 97% for the 1.5 mg/kg fed, 2.5 mg/kg fed, 2.5 mg/kg
fasted and 3.5 mg/kg fed groups, respectively (Table 5).
Maximum afoxolaner plasma concentrations were
observed at the ﬁrst blood sampling time on Day 1 of the
study (Fig. 2). Plasma concentrations of afoxolaner then
decreased over the month but remained above 90 ng/ml
on Day 33 for all dosage groups. Afoxolaner plasma con-
centrations showed dosage proportionally indicating linear
g/kg, administered to dogs in an oral solution against ticks (Dermacentor
cacyb) for Dose 1
 Day 16 Day 23 Day 28
26.1 28.1 27.3
(99.7%) 0.0 (100%) 0.0 (100%) 0.0 (100%)
y) for Dose 2
Day 16 Day 23 Day 28
25.2 24.7 18.4
8.2%) 0.6 (97.7%) 1.1 (95.5%) 0.2 (98.9%)
y) for Dose 3
Day 16 Day 23 Day 28
17.6 22.4 19.7
7.5%) 0.8 (95.6%) 5.2 (76.7%) 3.6 (81.5%)
cy) for Dose 4
Day 16 Day 23 Day 28
26.0 26.4 19.1
9.4%) 0.0 (100%) 0.1 (99.5%) 0.1 (99.4%)
cy) for Dose 5
 Day 16 Day 23 Day 28
24.2 27.0 27.0
99.5%) 0.0 (100%) 0.0 (100%) 2.1 (92.3%)
 mean of ln(count + 1).
d group.
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inetics over the range of 1.5–3.5 mg/kg (Fig. 2). There was
o statistical difference in the maximum concentrations or
verall exposure between dogs fed and fasted prior to treat-
ent. No adverse reaction was noted during the study at
ny time point on any dog.
With efﬁcacy established in fed as well as fasted dogs,
nd a strong indication of dosage proportionality, a fourth
tudy was conducted to evaluate the effects of repeated
osing.
.4. Study 4: assessment of 5 month repeat dosing on
fﬁcacy and safety in dogs
Over the ﬁve month period, mean effectiveness against
eas in the treated dogs was never less than 99% (Table 6).
he ﬁrst dose of afoxolaner in this test produced 83.5%
ean effectiveness against ticks in the treated dogs at
ay 2, and increased to 99% by the second week and then
o 100% for the remaining two weeks of the ﬁrst month
Table 7). For the following four months >98% efﬁcacy
as recorded against ticks for the ﬁrst tick challenges in
ach month and efﬁcacies of 100, 99, 82, 99 and 92% were
ecorded for the ﬁnal challenge for months 1 through 5,
espectively (Table 7).
For Dose 1 and Dose 2, early blood samples were taken
t 2, 6 and 12 h after treatment, for the remaining doses the
 and 12 h plasma collections were eliminated. The highest
lasma concentration of 0.82 g/ml was measured at the
 h time point after dose 1 (Fig. 3). Pharmacokinetic proﬁlesime (days)
 dosages in dogs following monthly dosing for 5 months.
for afoxolaner were observed to be predictable and repro-
ducible following multiple dosing (Fig. 3). Mean afoxolaner
plasma concentrations at 6 h were 0.82, 0.81, 0.97, 0.91,
and 0.80 g/ml for Doses 1 through 5, respectively. There
was no apparent difference in the trough concentrations as
mean minimum afoxolaner plasma concentrations (Cmin)
collected at 30 days post-dose were 0.09, 0.09, 0.12, 0.10
and 0.15 g/ml for Doses 1 through 5, respectively (Fig. 3).
These data indicate that steady state had been reached by
the 2nd dose. No adverse clinical signs were observed dur-
ing the study.
3.5. Study 5 – toxicity and symptomology in model
insects
A KD50 (50% knockdown concentration) value of 0.35 g
per cockroach was  determined. At the higher injected
dose, symptoms were observed within 10 min, initially
appearing as brief periodic wing ﬂuttering which pro-
gressed over time until the insects became uncoordinated
and had difﬁculty remaining upright. Once prostrate, cock-
roaches displayed periodic volleys of leg tremors. The rapid
onset and excitatory nature of toxicity suggested involve-
ment of a neuronal target.3.6. Study 6 – cockroach electrophysiology studies
By doing extracellular recordings on nerve 5 (N5) of
the metathoracic ganglion of American cockroaches, under
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Fig. 4. Evaluation of the isoxazoline, CPD I, in the American cockroach, P. americana,  cercal-reﬂex assay. (a) Diagram of the cerci and ventral nerve cord
(VNC).  Mechanical stimulation of hairs on the cerci produced action potentials which travel up the VNC. Integration of stimulatory and inhibitory input
at  the thoracic ganglia (T1–T3) determines the degree of nerve activity to the leg muscles. A suction electrode attached to motor nerve, N5, recorded the
efore a
owing inair  puff-induced efferent signals. (b) T3N5 response to a 50 ms  air puff b
puffs  induced action potentials with a spike frequency below 150 Hz. Foll
observed.
control conditions, a single air puff to the cerci produced a
rapidly adapting volley of action potentials with a spike fre-
quency between 75 and 175 Hz. Injection of CPD I (10 g)
into the body cavity produced no signiﬁcant effect on spon-
taneous action potential frequency. However, adaptation
of the air puff-induced N5 activity was inhibited by CPD I,
resulting in a strong increase of spike frequency (Fig. 4b).
Similarly, bath perfusion of CPD I (10 mM)  induced a strong
increase in the air puff-induced spike frequency indicating
increased excitability due to blocking of inhibitory neu-
ronal activity (Fig. 4c). The fact that the spontaneous action
potential frequency remained unaffected suggested that
action at the neurotransmitter receptors was a more likely
target than action at voltage-gated ion channels.
As the neurotransmitters involved in the cercal reﬂex
include both excitatory nicotinic acetylcholine receptors
(nAChRs) and inhibitory GABA receptors (GABARs), action
of CPD I was investigated on both neurotransmitter recep-
tors. Although no effect was observed on nAChRs (data not
shown), the compound potently inhibited GABA-induced
currents in American cockroach thoracic neurons. CPD Ind after injection with CPD I. (c) In the presence of saline or DMSO, air
jection of 1 l CPD I (10 M) a strong increase in the air-puff response is
inhibited GABA-induced currents with an IC50 value of
10.8 nM (Fig. 5) with prolonged saline rinse (>15 min)
resulting in partial recovery of the GABA response.
3.7. Study 7 – oocyte injection and voltage clamp studies
Application of GABA (100 M)  induced a strong inward
current in oocytes expressing the Drosophila RDL receptor.
Perfusion of afoxolaner produced a dose-dependent inhi-
bition in the GABA response with an IC50 value of 3.7 nM
as shown in Fig. 6. This inhibition failed to reverse follow-
ing extended saline washout. In Drosophila,  resistance to
cyclodiene insecticides is associated with a single amino
acid substitution of serine for alanine at residue 302 of the
rdl gene (Ffrench-Constant et al., 2000). Xenopus oocytes
expressing A302SRDL were challenged with afoxolaner at
0.1, 1, and 10 nM to compare potency relative to that
observed with wtRDL. As shown in Fig. 7, there was  no
statistically signiﬁcant difference observed between wtRDl
and A302SRDL at any of the concentrations, suggesting that
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.8. Study 8 – cross-resistance studies
As shown in Fig. 8, afoxolaner was highly potent on
anton-S ﬂies with an LD50 value of 0.2 g/vial (95% conﬁ-
ence interval = 0.1–0.4 g/vial). Although this insecticide
s an order of magnitude less potent against the susceptible
train than dieldrin (LD50 value of 0.02), excellent potency
as observed against the RDL strain, as predicted by the
eceptor studies. RDL ﬂies exhibited comparable sensitiv-
ty with a resistance ratio value (RR, expressed as RDL
afoxolanercontrol
0.
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Concent
ig. 6. Inhibitory effect of afoxolaner on expressed wtRdl GABA-gated chloride ch
 holding potential of −60 mV and repeatedly stimulated with pulses of 100 M
erfusion of afoxolaner inhibited the GABA response (inset, 100 nM afoxolaner) in, neurons. Dissociated neurons were clamped at a holding potential of
e). Perfusion of CPD I inhibited the GABA response (inset, dashed trace)
 rinse a partial recovery of the GABA response (inset, dotted trace) was
LD50/Canton-S LD50) of only two. In contrast, the RDL ﬂies
exhibited strong resistance to dieldrin (RR > 5000) consis-
tent with earlier reports (Bloomquist, 1993). Based on the
mode of action and differences in receptor interaction, it is
unlikely that ﬂeas and ticks carrying the rdl gene mutation
and thereby resistant to dieldrin will demonstrate cross-
resistance to afoxolaner.
4. DiscussionData generated in these research studies provided
evidence of the safety and month-long effectiveness of
afoxolaner against ﬂeas and ticks on dogs following oral
100010010
ration (nM)
annels. Xenopus oocytes expressing the wtRdl receptor were clamped at
 GABA to induce activation of GABA-gated Cl− currents (Inset, control).
 a dose-dependent manner with an IC50 = 3.7 nM.
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Fig. 7. Inhibitory effect of afoxolaner, on GABA-gated Cl− currents
recorded from Xenopus oocytes expressing either wtRdl or A302SRdl (resis-
tant) receptors. Oocytes were recorded using TEVC with a holding
potential of −60 mV.
administration at 2.5 mg/kg. The in vitro discovery results
showed that afoxolaner was more potent than any other
compound ever tested in this membrane feeding system,
including the avermectins (Zakson et al., 2001). This in vitro
assay was not only an important tool for estimation of com-
pound potency in the discovery process, but established
a preliminary in vivo target of 0.16 g/ml as a blood level
required in a dog for complete ﬂea effectiveness for 30 days.
The 0.16 g/ml level was chosen because it provided 100%
control at the 24 h in vitro observation and a 24 h in vivo
challenge was to be used for ﬂeas on dogs. In subsequent
work conducted with formulated afoxolaner in dogs, the
EC90 for ﬂeas was determined to be 0.023 g/ml (Letendre,
2014).
With strong evidence that blood containing afoxolaner
could effectively control ﬂeas, Study 2 was initiated and
represented the ﬁrst time afoxolaner was evaluated in a
dog (n = 1). That study revealed effectiveness of afoxolaner
against both ﬂeas and ticks beyond a month following
0
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dieldrin Canton-S
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RR = 2
RR >5,000
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Fig. 8. Contact toxicity bioassay of wild type (Canton-S) and cyclodiene-
resistant (Rdl) strains of Drosophila. Glass vials were treated with test
compounds and mortality measurements taken 72 h after introduction
of  ﬂies. The resistance ratio (RR) corresponds to the Rdl LD50/Canton-S
LD50.tology 201 (2014) 179–189
a single 2.5 mg/kg oral administration. In addition to
attaining a blood concentration capable of providing ﬂea
control at the end of a month, it appeared that this blood
level also was  fully effective for ticks.
Study 3 provided a dosage titration of afoxolaner in dogs
(n = 3) using oral administration. Results supported the pre-
viously observed ﬂea and tick effectiveness for one month.
Moreover, plasma level data and efﬁcacy results indicated
that there was  no apparent prandial effect on the systemic
absorption and effectiveness of afoxolaner. The compound
was  well absorbed with concentrations above those needed
for effectiveness achieved at the ﬁrst sampling time on
the ﬁrst day of the study and the plasma concentrations
remained high enough to support effective ﬂea and tick kill
for the entire 33 days of the study. The pharmacokinetic
proﬁles suggested dose proportionality over the range of
doses tested, providing further indication of a good safety
proﬁle, and no dog showed an adverse event attributable
to the drug at any time during this study.
Study 4 was conducted to explore the effects of repeated
dosing and dogs (n = 6) received 5 monthly doses of afox-
olaner in the experimental oral solution. Effectiveness
results showed nothing less than 99% against ﬂeas during
the 26 challenges. Effectiveness against ticks at the end of
each month (immediately before the next monthly dose)
was  also very good with values of 100, 99, 82, 99 and 92%
for months 1 through 5, respectively. The pharmacokinetic
proﬁles observed in this study were remarkably consistent
with similar Cmax and Cmin for each monthly dose, and min-
imal accumulation of afoxolaner recorded over repeated
dosages.
Veterinary clinical examinations conducted through-
out the study showed no indication of adverse effects.
The lack of accumulation following multiple dosing, the
observed safety, and the sustained effectiveness conﬁrmed
the potential for afoxolaner to become a convenient and
safe ectoparasiticide for use in dogs.
The mode of action studies demonstrated that afox-
olaner and compounds of the isoxazoline class control
insects by inhibition of GABA-gated chloride ion chan-
nels (Ozoe et al., 2010; Gassel et al., 2014). It can be
expected that afoxolaner will act on ﬂeas and ticks in a
similar way. GABA-gated chloride ion channels are the
target of ivermectin, ﬁpronil, and cyclodienes; however
ivermectin binds to a distinct site and activates rather than
blocks GABA-gated chloride channels (Garcia-Reynaga
et al., 2013; Gassel et al., 2014). It has been well estab-
lished that replacement of alanine with serine at position
302 of the rdl gene confers strong resistance to cyclodienes
and moderate resistance to ﬁpronil in some arthropods
(Ffrench-Constant et al., 2000; Bloomquist et al., 1992;
Bloomquist, 1993). It is particularly noteworthy that no sig-
niﬁcant difference in afoxolaner sensitivity was  observed in
Drosophila toxicity or receptor studies for wild type versus
A302S mutants. These ﬁndings indicate that afoxolaner
binds to the target in a manner distinct from cyclodienes
and phenylpyrazoles. Preliminary biochemical studies with
3H-CPD I (unpublished but reported by Cordova et al., 2010)
further support a distinct binding site for this chemistry.
Consequently, one would expect afoxolaner to exhibit full
potency on insects that bear the A302S mutation. Further,
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ity of the avermectins against the cat ﬂea (Siphonaptera: Pulicidae). J.W.L. Shoop et al. / Veterinar
t is unlikely that insects and acari which exhibit resistance
o commonly used insecticides will show cross-resistance
o afoxolaner given its unique mode of action.
In summary, the discovery studies reported here
emonstrated the ability of afoxolaner to control ﬂeas and
icks on dogs for more than a month when administered
rally at the relatively low dose of 2.5 mg/kg. The pre-
ictable pharmacokinetic proﬁles of the compound, the
bsence of health abnormalities in treated dogs, together
ith the remarkable efﬁcacy proﬁle, and well-elucidated
ode of action made afoxolaner the isoxazoline of choice
or further development.
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